cyrilzakka/clinical-trials huggingface dataset:
Clamshells Exercise and Vastrus Medialis Oblique Strengthening Exercise on Patellofemoral Pain Syndrome

PFPS, also known as patellofemoral pain syndrome, is a prevalent musculoskeletal condition that primarily affects adolescents and young adults. When engaging in various activities, such as stair climbing, running, jumping, kneeling, or prolonged sitting, it is characterized by aching pain in the peripatellar region. Any disruption of these would result in abnormal PFJ overloading. Normal patellar tracking on the trochlea groove relies on the coordination and balance of many structures, including soft tissues, muscles, tendons, ligaments, and the shape of articular surfaces around the knee joint. Research in a variety of fields has received support the therapeutic exercise known as "clamshells" for stabilizing the pelvis by strengthening the hip abductors and external rotators.VMO strengthening exercises are also essential in keeping the patella in the trochlear groove and lowering the lateral vector force on the patellofemoral joint. This research aims to evaluate the effects of clamshells exercise and Vastrus medialis oblique strengthening exercise in patients with Patellofemoral pain syndrome.

The study would be randomized clinical trial. Total fourty two subjects will be assigned randomly by using lottery method into two groups. Group A will be given clamshell exercise with baseline treatment while Group B will receive targeted vastrus medialis oblique strengthening exercise with baseline treatment. After confirmation of diagnosis with physical examination as well as zohlar's test /20 cm step down test are recommended. Numeric pain rating scale (NPRS) and Lower extremity functional scale (LEFS) would be used as an outcome measure tools for pain and functional limitation respectively. Measurements will be taken at (Baseline and at the end of treatment session). The collected data will be analyzed in Statistical Package for the Social Sciences (SPSS) 25.0. Parametric/non-parametric tests will be applied after testing normality of data.


Eligibility Criteria:
Inclusion Criteria:

* Age 18 to 40years
* Both Genders (male \& female)
* Unilateral or bilateral knee pain for at least 1-3 month,
* Pain provoked by at least 3 functional activities ( ascending/descending stairs, kneeling, jumping, running, squatting,hopping,prolonged sitting)
* Average NPRS score above 3 out of 10 during previous week.
* Knee pain on stepping down from 20cm step height.

Exclusion Criteria

* Previous history of patellar subluxation or dislocation
* Knee surgery within previous year
* History of knee joint pathologies ( meniscus,ligament injuries,)
* Any fracture of lower extremity
* Massive effusion/any abnormal deformity of knee joint.
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects with Hypertension and Chronic Kidney Disease (CKD) with Albuminuria

This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and safety of 25 mg QD lorundrostat (an aldosterone synthase inhibitor \[ASI\]) in addition to a SGLT2i for the treatment of hypertension in subjects with CKD and albuminuria while receiving stable treatment with an Angiotensin-converting enzyme inhibitor (ACEi) or an Angiotensin receptor blocker (ARB). Subjects will be at least 18 years old with hypertension, and mild to severe CKD with albuminuria at the Screening Visit.

The study consists of up to a 2-week Screening period, a 2-week run-in period where subjects will either begin study provided dapagliflozin 10 mg or continue on their regularly prescribed SGLT2i, and two DB 4-week treatment periods separated by a 4-week washout period. Subjects will be randomized (1:1) to two treatment sequences: lorundrostat-placebo (LP) and placebo-lorundrostat (PL).

Eligibility Criteria:
Major Inclusion Criteria:

1. At Screening, UACR of 200-5000 mg/g, inclusive, in first morning urine void
2. At Screening, eGFRs of ≥30 mL/min/1.73 m2
3. At Screening, AOBP SBP of 135-180 mmHg, inclusive
4. On a stable treatment with an ACEi or ARB for at least 2 months prior to Screening
5. At Screening, body mass index (BMI) of \>18 kg/m2

Major Exclusion Criteria:

1. Subjects with known hypersensitivity to lorundrostat or any of its respective excipients
2. Subjects with known hypersensitivity to dapagliflozin or any of its respective excipients (subjects beginning dapagliflozin only)
3. At Screening, serum potassium \>5.0 mmol/L
4. History of clinically significant hyponatremia within 1 year prior to Screening
5. Use of epithelial sodium channel (ENaC) inhibitors or Mineralocorticoid receptor antagonist (MRAs), including, but not limited to amiloride, triamterene, spironolactone, eplerenone, finerenone, from 4 weeks prior to the Screening Visit and during study participation. With the exception of MRAs in primary aldosteronism
6. Medical history of kidney disease related to autoimmune diseases (lupus, anti-neutrophil cytoplasmic antibody \[ANCA\] vasculitis), multiple myeloma or other known paraproteins, infiltrative diseases of the kidney, obstructive nephropathy, cystic kidney diseases, and renal transplantation
7. Medical history of advanced liver disease, including cirrhosis
8. Medical history of active autoimmune disease or recent (within 30 days) or anticipated need for immunosuppressive therapy
9. Diabetes mellitus with a glycosylated hemoglobin (HbA1c) \>10% (\>86 mmol/mol) at Screening
A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder

The purpose of this study is to assess the effects of an acute dose of BNC210 compared to placebo on reducing anxiety provoked by a speaking challenge and measured using the Subjective Units of Distress Scale (SUDS) in patients with Social Anxiety Disorder (SAD).

This is a randomized, double-blind, placebo-controlled, 3-arm, parallel-group, multi-center study. Participants will attend a Screening Visit to confirm eligibility and then return to the clinic within 14 days to be randomized into the study. Randomized participants will receive a single dose of their allocated study intervention (225 mg BNC210, 675 mg BNC210 or placebo) and approximately 1 hour later participate in a speaking challenge. After 1 week, a safety follow-up assessment will be conducted by phone/video conference.

Eligibility Criteria:
Inclusion Criteria:

* Participant has a current diagnosis of Social Anxiety Disorder (SAD) as defined in DSM-5 and confirmed by Structured Clinical Interview for DSM-5 Disorders - Clinical Trials version (SCID-5-CT).
* Liebowitz Social Anxiety Scale (LSAS) total score of ≥70
* Suitable contraception use in line with protocol requirements
* Ability to swallow tablets

Exclusion Criteria:

* History of schizophrenia, bipolar disorder, or psychotic disorders, or has a current clinically predominant diagnosis of any other Axis I disorder, other than SAD
* Hamilton Rating Scale for Depression (HAM-D) score of ≥18
* Moderate or severe alcohol-use disorder, or any other substance-use disorder (any severity) in the past 12 months
* Use of psychotropic medications within 30 days of screening. Daily use of benzodiazepines within 90 days of screening.
* Previous participation in a study that involved a speaking challenge.
* Any clinically significant medical history or findings as determined by the Investigator that could interfere with the objectives of the study or put the participant at risk
Dapagliflozin in Pulmonary Arterial Hypertension

The purpose of this study is to investigate the effects of dapagliflozin on exercise capacity and hemodynamics in patients with pulmonary arterial hypertension

The objective of this study is to evaluate the effects of oral dapagliflozin (Forxiga®) treatment versus placebo in clinically stable patients with pulmonary arterial hypertension or CTEPH on background vasodilator combination therapy on cardio-pulmonary exercise capacity, pulmonary vascular hemodynamics, RV function and metabolomic profile of the pulmonary vascular endothelium.

Eligibility Criteria:
Inclusion Criteria:

* A diagnosis of PAH group 4 or group 1 in any of the following subtypes:

  * Idiopathic PAH (iPAH)
  * Heritable PAH (hPAH)
  * Connective tissue disease associated PAH (aPAH)
  * Associated with congenital heart disease (aPAH)
  * In case of PH in group 4, no further invasive treatment including pulmonary endarterectomy or pulmonary balloon angioplasty must be planned at time of inclusion.
* Symptomatic PAH in WHO functional class II-III as assessed by the screening clinician.
* Clinically stable patients on pulmonary vasodilator treatment with PDE5i, ERA, PA/IPA alone or in combination without considerations from the treating physician team towards treatment escalation and a treatment duration of at least four weeks. Clinical stability defined as stable symptoms without progression as assessed by treating clinician and without the need for unplanned hospital admissions due to worsening PAH within three months of screening.
* Fertile women (\< 50 years of age) must use safe contraceptives (Intra uterine device or hormonal contraception) for the duration of the study and have a negative pregnancy test
* Able to understand the written patient information in Danish and give informed consent.
* Age ≥ 18 years
* Ability to perform cardio pulmonary exercise test

Exclusion Criteria:

* Known allergy to the study medication
* Treatment with an SGLT2i within 6 months prior to baseline
* Type 1 or type 2 diabetes
* Impaired renal function with an eGFR \< 30 mL/min/m2 within four weeks of screening
* Severe liver dysfunction (Child-Pugh class c)
* Listed for lung transplantation at the time of screening
* Planned initiation of iv prostacyclin therapy/ IPA or current dose escalation planned
* Planned pulmonary endarterectomy or pulmonary balloon angioplasty.
* LVEF \< 50%
* Diagnosis of PAH group 2, 3 or 5
Host-pathogen Interactions, Immune Response, and Clinical Prognosis at COVID-19 - the CoVUm Trial

The project aims to clarify how immunity to SARS-CoV2 develops in humans and to investigate the possibility of finding patients with a particularly effective, neutralizing antibody response for future treatment. The project also aims to detail the virus's damage mechanisms in tissue.

There is currently a mounting body of evidence regarding the pathogenesis of COVID-19 caused by SARS-CoV2. By gaining more knowledge about the mechanisms in the development of viral pneumonia and the influence of other organ systems at SARS-CoV2, we believe that in the future it is better to be able to identify precisely those persons who are at risk of serious illness. To this we will gain knowledge of how humans develops immunity to the virus and also how human epigenetic (acquired) ability to activate inflammatory genetic systems can limit the harmful effects of the virus. Thus, patients who have had mild or no symptoms are just as interesting from a study point of view as those who have had severe symptoms. Hopefully, such understanding can also contribute to other opportunities for targeted treatment (by identifying patients who can mount effective inborn and adaptive host defenses) in order to prevent severe disease and death in pandemic corona infection.

Eligibility Criteria:
Inclusion Criteria:

* Patients between 15-100 years with SARS-CoV2 or influenza
* Patients admitted for COVID-19 or Influenza-caused pneumonia/ pneumonitis at the Departments of Infectious Diseases or ICU, Umeå University Hospital, Örebro hospital, Karlstad hospital and Västerås hospital
* Patients with COVID-19 who are treated in outpatient care at the infectious Diseases Clinic, Umeå University Hospital, Sweden
* Patients who give written informed consent to participate in the study for the entire follow- up period of 5 years.

Exclusion Criteria:

* Age less than 15 years
Interstitial Lung Disease Research Unit Biobank

Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.

The University of Kansas ILD and Rare Lung Disease clinic sees hundreds of new patients per year. The investigators would like to leverage this resource to develop an Interstitial Lung Disease Research Unit (ILDRU) repository and database to help develop new methods for early diagnosis, uncover underlying genetic and environmental risk factors, as well as potential treatment targets in the broad range of interstitial lung diseases and rare lung diseases (RLD).

Eligibility Criteria:
Inclusion Criteria:

1. The participant is a patient at TUKHS or has agreed to participate in a study approved by the KUMC Human Research Protection Program (HRPP)
2. The participant is being followed for the presence of autoimmune disease, ILD or other rare lung diseases at TUKHS.
3. The participant is ≥ 18 years of age.
4. The participant has signed an approved consent for this study (living patients only)
Single and Multiple Dose Escalation Trial of an Intravenous Antibiotic RC-01

A Phase 1 study of the safety, tolerability and pharmacokinetics of a new antibiotic (RC-01). In Part 1 cohorts of healthy adults will participate in a single dose escalation study of increasing intravenous doses of RC-01. In Part 2 cohorts of healthy adults will participate in a multiple dose escalation study of increasing intravenous doses of RC-01 given either twice daily or three times daily.


Eligibility Criteria:
Inclusion Criteria:

* Healthy subjects
* Agrees to be available for all study visits and cooperate fully with the requirements of the study protocol, including the schedule of assessments
* Willing and able to provide written informed consent

Exclusion Criteria:

* Underlying hepatic, renal, metabolic, cardiovascular or immunologic disorders
* Unable to cooperate fully with the requirements of the study protocol, including the schedule of assessments, or likely to be non-compliant with any study requirements
* Women who are pregnant and/or nursing
VIdeo Clips for Diagnostic Evaluation of Obstructive Sleep Apnea in Children

Obstructive sleep apnea (OSA), which occurs in 1-4% of children, is a serious condition where a person stops breathing periodically during sleep because their airway closes. Untreated, it is associated with high blood pressure, behavioural problems, and lower quality of life. While early diagnosis and treatment are critical, there are significant barriers to access to a sleep study (the best diagnostic test). Questionnaires and overnight oxygen level recordings are limited in their ability to identify OSA. Better screening tools are needed to identify and prioritize children for sleep study testing. Short video clips, recorded using smartphones by parents, may be a useful tool to identify children at risk of OSA who would most benefit from a sleep study. The study aims to evaluate the ability of home smartphone video clips as a screening tool for moderate-severe OSA in children referred for a sleep study. The utility of video clips will also be compared to questionnaires and overnight oxygen saturation recordings. The investigators believe that the video clips will be able to predict moderate-severe OSA in children and that they will be better than standard clinical questionnaires or oxygen recordings. This multi-centre study will include 625 children referred for sleep studies for suspected OSA. Parents will be asked to record short video clips of their child sleeping, which will be rated for the presence and severity of OSA. Children will then undergo a sleep study, and parents will complete a questionnaire about sleep symptoms. Oxygen level recordings will be extracted from the sleep study. The diagnostic accuracy of video clips will be determined and compared to the questionnaire and oxygen level recording. This new approach to screening for pediatric OSA using widely available technology will allow children at the highest risk for moderate-severe OSA to be diagnosed and treated earlier, minimizing the risk of long-term complications.


Eligibility Criteria:
Inclusion Criteria:

* 2-18 years old
* referred for diagnostic PSG to assess for OSA at their local tertiary care centre
* parent/caregiver has access to mobile technology

Exclusion Criteria:

* previous diagnosis of sleep-disordered breathing based on PSG in the last five years
* unable to cooperate for PSG
* clinician-suspected presence of central sleep apnea or central hypoventilation
* genetic or congenital syndrome
* non-verbal
* use of PAP therapy or tracheostomy
* parent/caregiver does not speak English or French
Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis.

The investigators will compare the common treatment for cutaneous leishmaniasis with intra-lesional Pentostam to fractional CO2 laser with topical application of Pentostam.

Outcome will be final scar appearance assesd by two dermatologist and pain measurement by VAS.

20 healthy patients diagnosed will cutaneous leishmaniasis with more than one lesion will be recruited.

Half of the lesions will be treated with intra-lesional injections of Pentostam, and the other half by CO2 laser with topical application of Pentostam.

Each lesion will recieve 3 treatments, one month apart between treatments. The patients will scale pain level of each treatment. Final scar appearance will be assessed by two dermatologists, without knowing what treatment was applied to each lesion.

Eligibility Criteria:
Inclusion Criteria:

* Objective cutaneous leishmaniasis diagnosis.
* More than one Lesion

Exclusion Criteria:

* Previous treatment
* Abnormal scarring
Oral Contraceptive and Strength Training

Cross sectional study investigating the effect of strength training in users and non-users of oral contraceptives (OC) (2nd generation OC)


Eligibility Criteria:
Inclusion Criteria:

* 18.5 - 30 years
* BMI \< 30

Exclusion Criteria:

* Medicine influencing protein turnover
* Surgery on the knee
* Arthritis
* Diabetes
* Smoking
* irregular menstruation (\<24 days or \>35 days cycles)
* Non-users: not have used contraceptives for the last 3 months.
* Unstable weight (+/- 5 kg within the last 6 months)
* Regular training/exercise more than 2 hours/week for the last 6 months. Maximum 70 km of cycling transport/week.
* Strength training \>1time/month for the last 6 months.
* Pregnancy
* Diet og eating disorder
* Can not read or understand danish
Circulating Tumor DNA as a Prognostic Marker in Patients With Pancreatic Cancer

The aim of this study is to determine the usefulness of circulating tumor DNA as a prognostic factor in patients with pancreatic cancer.

There is currently no strong prognostic factor in pancreatic cancer. K-ras is the most commonly mutated gene in pancreatic cancer, with a mutation rate of 75% to 95%. These high mutation rates are expected to be useful for diagnosis and prognostic factors in future. Currently, K-ras mutation tests are often performed in tissues, and there are various limitations, in particular, limited obtaining of sufficient tissues. In this regard, analyzing the prognosis of pancreatic cancer through non-invasive blood testing has significant advantages. And Prognosis analysis through blood tests can be done through blood circulating tumor DNA. The relationship between prognosis and blood circulating tumor DNA has already been studied in other cancers such as colorectal cancer, and there have been several studies in pancreatic cancer. However, there are not many research results yet, and there are cases in which the results differ from study to study. Therefore, the purpose of this study is to compare the overall survival of patients with pancreatic cancer diagnosed by EUS-FNA according to the presence and amount of blood circulating tumor DNA with K-ras mutation.

Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with pancreatic cancer through EUS-FNA.

Exclusion Criteria:

* Severe mental illness
* Severe co-morbidity (ESRD, Advanced COPD, severe Heart failure, poorly controlled blood sugar)
* Pregnancy
* Patients who have received chemotherapy
* Coagulopathy
Cranberry Juice in the Prevention of Urinary Tract Infections in Children

The objective of the study is to determine whether recurrences of urinary tract infection in children can be prevented with cranberry juice.

Five percent of children have at least one UTI episode and 30% of these episodes recur. Recurrences and the risk of renal damage are indications for long term antimicrobial prophylaxis, but emerging antimicrobial resistance underlines the need for alternatives. The bacteria causing urinary tract infection arise from the stools. Dietary changes can alter the balance of faecal bacteria. Vaccinium berries and products containing lactobacilli have been shown to act against the coliform bacteria that cause most urinary tract infections. In our previous study cranberry juice was effective in preventing symptomatic recurrences of urinary tract infections in women. The objective of our study is to determine whether recurrences of urinary tract infection in children can be prevented with cranberry juice.

Eligibility Criteria:
Inclusion Criteria:

* Urinary Tract Infection 0-2 months priorly

Exclusion Criteria:

* Antibiotic Prophylaxis
Effectiveness of a Home-based Telehealth Exercise Program on Adherence and Performance in Handball Players

The objective of this clinical trial is to determine whether Physitrack®, a telerehabilitation platform, improves players' adherence to exercise programs. The secondary objectives are to assess whether its use enhances players' jumping ability (speed, height, flight time) and to evaluate the usability of the Physitrack® application from the players' perspective, considering aspects such as ease of use and user satisfaction.

The main questions this study aims to answer are:

Do exercise programs conducted through an online telemedicine platform achieve good adherence among handball players? Do exercise programs carried out via this telerehabilitation platform improve performance in vertical jumping? Do exercise programs performed using this platform provide good usability and user satisfaction results? To answer these questions, researchers will compare two groups following different exercise programs. The study will analyze whether, in addition to improving adherence, a specific program designed to enhance vertical jumping yields better results compared to a more general exercise program.

Participants:

Will perform a vertical jump test using force plates. Must follow the assigned eight-week exercise program according to randomization.

Will repeat the vertical jump test at the end of the program.


Eligibility Criteria:
Inclusion Criteria:

* Men over 18 years old who are part of the Móstoles Handball Club team

Exclusion Criteria:

* Injured players at the start of the study and players who do not wish to participate
Comparison of Different Treatments for Overactive Bladder Syndrome

This study aims to investigate the effects of pelvic floor muscle exercises, electrical stimulation and taping in patients with overactive bladder


Eligibility Criteria:
Inclusion Criteria:

* Women
* Being Volunteered to participate
* Diagnosed as overactive bladder

Exclusion Criteria:

* Pregnant women
* Patients with a comorbid neurological disorder
* A mental problem that may prevent cooperation and evaluation
* Acute infection
* Sensory loss
* Malignancy